Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA polymerase III subunit alpha PolC is the essential replicative enzyme responsible for chromosomal DNA synthesis in low G+C Gram-positive bacteria, including pathogens such as Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis (UniProt P13267). Unlike the DNA polymerase III (DnaE) found in Gram-negative bacteria like Escherichia coli, PolC possesses an intrinsic 3'-5' exonuclease proofreading activity and serves as the primary replicase for both leading and lagging strands in these organisms (Low et al., 2003; PMID: 12805257). Because PolC is structurally distinct from eukaryotic DNA polymerases, it represents a highly selective target for the development of narrow-spectrum antibiotics that do not interfere with human DNA replication (Daly et al., 2000; PMID: 10952585). Inhibitors of PolC, such as 6-anilinouracils, typically act by competing with dGTP for binding, thereby halting bacterial DNA replication and exerting a bactericidal effect (Wright & Brown, 1990). This target is particularly significant for addressing multi-drug resistant Gram-positive infections where traditional antibiotics may fail.
Inhibition of DNA synthesis by competitive binding with deoxyguanosine triphosphate (dGTP) at the enzyme active site, which prevents the formation of the ternary complex and leads to termination of DNA chain elongation (Wright & Brown, 1990; PMID: 2190303).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA polymerase III subunit alpha PolC (PolC).